[1]
|
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41: 19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005 |
[2]
|
郑轩, 胡毅. 晚期非小细胞肺癌患者抗PD-1治疗前后血清TNF-α水平变化与疗效的关系[J]. 解放军医学院学报, 2019, 40: 231-234. doi: 10.3969/j.issn.2095-5227.2019.03.008 |
[3]
|
Genova C, Rossi G, Tagliamento M, et al. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives[J]. Expert Rev Respir Med, 2020, 14: 367-383. doi: 10.1080/17476348.2020.1714441 |
[4]
|
Atal S, Asokan P, Jhaj R. Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update[J]. J Clin Pharm Ther, 2020, 45: 580-584. doi: 10.1111/jcpt.13121 |
[5]
|
Singh SS, Dahal A, Shrestha L, et al. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy[J]. Curr Med Chem, 2020, 27: 5274-5316. doi: 10.2174/0929867326666190222183219 |
[6]
|
Arbour KC, Riely GJ. Systemic Therapy for Locally Adv-anced and Metastatic Non-Small Cell Lung Cancer: A Review[J]. JAMA, 2019, 322: 764-774. doi: 10.1001/jama.2019.11058 |
[7]
|
Iwama E, Goto Y, Murakami H, et al. Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401[J]. Oncologist, 2020, 25: 306-e618. doi: 10.1634/theoncologist.2019-0728 |
[8]
|
Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Anna Oncoly, 2020, 31: 1056-1064. doi: 10.1016/j.annonc.2020.04.478 |
[9]
|
Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial[J]. Lancet, 2017, 390: 29-39. doi: 10.1016/S0140-6736(17)30565-2 |
[10]
|
Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study[J]. Lancet Respir Med, 2019, 7: 437-446. doi: 10.1016/S2213-2600(19)30053-0 |
[11]
|
Huang SH, Huang AC, Wang CC, et al. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control[J]. Thorac Cancer, 2019, 10: 2274-2281. doi: 10.1111/1759-7714.13221 |
[12]
|
Nishio M, Felip E, Orlov S, et al. Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase Ⅱ Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC[J]. J Thorac Oncol, 2020, 15: 609-617. doi: 10.1016/j.jtho.2019.11.006 |
[13]
|
Soria JC, Tan DSW, Chiari R, et al. First-line Ceritinib Versus Platinum-Based Chemotherapy in Advanced ALK-rearranged Non-Small-Cell Lung Cancer (ASCEND-4): A Randomised, Open-Label, Phase 3 Study[J]. Lancet, 2017, 389: 917-929. doi: 10.1016/S0140-6736(17)30123-X |
[14]
|
Cho BC, Kim DW, Bearz A, et al. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken With a Low-Fat Meal Versus 750 mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearran-ged Metastatic Non-Small Cell Lung Cancer (NSCLC)[J]. J Thorac Oncol, 2017, 12: 1357-1367. doi: 10.1016/j.jtho.2017.07.005 |
[15]
|
Cho BC, Obermannova R, Bearz A, et al. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study[J]. J Thorac Oncol, 2019, 14: 1255-1265. doi: 10.1016/j.jtho.2019.03.002 |
[16]
|
Huber RM, Hansen KH, Paz-Ares Rodríguez L, et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial[J]. J Thorac Oncol, 2020, 15: 404-415. doi: 10.1016/j.jtho.2019.11.004 |
[17]
|
Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase Ⅲ ALTA-1L Trial[J]. J Clin Oncol, 2020, 38: 3592-3603. doi: 10.1200/JCO.20.00505 |
[18]
|
Zhu VW, Lin YT, Kim DW, et al. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC[J]. J Thorac Oncol, 2020, 15: 1484-1496. doi: 10.1016/j.jtho.2020.04.019 |
[19]
|
Baldacci S, Besse B, Avrillon V, et al. 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort[J]. Ann Oncol, 2020, 31: 865-874. doi: 10.1016/j.annonc.2020.08.1663 |
[20]
|
Liang H, Wang M. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis[J]. Onco Targets Ther, 2020, 13: 2491-2510. doi: 10.2147/OTT.S231257 |
[21]
|
Recondo G, Che J, Jänne PA, et al. Targeting MET Dysregulation in Cancer[J]. Cancer Discov, 2020, 10: 922-934. doi: 10.1158/2159-8290.CD-19-1446 |
[22]
|
Schuler M, Berardi R, Lim WT, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase Ⅰ trial[J]. Ann Oncol, 2020, 31: 789-797. doi: 10.1016/j.annonc.2020.03.293 |
[23]
|
Bang YJ, Su WC, Schuler M, et al. Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts[J]. Cancer Sci, 2020, 111: 536-547. doi: 10.1111/cas.14254 |
[24]
|
Heist RS, Wolf J, Seto T, et al. OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study[J]. J Thorac Oncol, 2019, 14: S1126-S1138. http://www.sciencedirect.com/science/article/pii/S1556086419333490 |
[25]
|
Wolf J, Neal JW, Mansfield AS, et al. 1346P Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients[J]. Ann Oncol, 2020, 31: S863-S874. doi: 10.1016/j.annonc.2020.08.1660 |
[26]
|
Goodwin K, Ledezma B, Heist R, etal. MO01.04 Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial[J]. J Thorac Oncol, 2021, 16: S16-S17. http://www.sciencedirect.com/science/article/pii/S1556086420309187 |
[27]
|
Camidge D, Janku F, Bueno A, et al. 1490PDA phase Ⅰa/Ⅱa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours[J]. Ann Oncol, 2019, 30: 1128-1132. http://www.researchgate.net/publication/336192491_1490PDA_phase_IaIIa_trial_of_Sym015_a_MET_antibody_mixture_in_patients_with_advanced_solid_tumours |
[28]
|
Camidge D, Janku F, Alejandro MB, et al. Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14Δ)[J]. J Clin Oncol, 2020, 38: 9510-9519. doi: 10.1200/JCO.2020.38.15_suppl.9510 |
[29]
|
Gu Y, Sai Y, Wang J, et al. Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor[J]. Eur J Pharm Sci, 2019, 136: 104938. doi: 10.1016/j.ejps.2019.05.016 |
[30]
|
Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol, 2020, 21: 373-386. doi: 10.1016/S1470-2045(19)30785-5 |
[31]
|
Shun L, Jian F, Xingya L, et al. Phase Ⅱ study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+)[J]. J Clin Oncol, 2020, 38: 9519-9529. doi: 10.1200/JCO.2020.38.15_suppl.9519 |
[32]
|
Gan HK, Millward M, Hua Y, et al. First-in-Human Phase Ⅰ Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity[J]. Clin Cancer Res, 2019, 25: 4924-4932. doi: 10.1158/1078-0432.CCR-18-1189 |
[33]
|
Wu YL, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial[J]. Lancet Respir Med, 2020, 8: 1132-1143. doi: 10.1016/S2213-2600(20)30154-5 |
[34]
|
Paik P, Cortot A, Felip E, et al. A phase Ⅱ trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study[J]. Ann Oncol, 2019, 30: ii66-ii78. http://www.sciencedirect.com/science/article/pii/S0923753419301310 |
[35]
|
Markham A. Tepotinib: First Approval[J]. Drugs, 2020, 80: 829-833. doi: 10.1007/s40265-020-01317-9 |
[36]
|
Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond[J]. NPJ Breast Cancer, 2020, 6: 2784-2795. http://www.researchgate.net/publication/339882217_Clinical_development_of_immunotherapies_for_HER2_breast_cancer_a_review_of_HER2-directed_monoclonal_antibodies_and_beyond |
[37]
|
Xu F, Yang G, Xu H, et al. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China[J]. Thorac Cancer, 2020, 11: 679-685. doi: 10.1111/1759-7714.13317 |
[38]
|
Tsurutani J, Park H, DoiT, et al. OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or-Mutated Advanced Non-Small-Cell Lung Cancer[J]. J Thorac Oncol, 2018, 13: S324. http://www.sciencedirect.com/science/article/pii/S1556086418312024 |
[39]
|
Smit E, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01[J]. J Clin Oncol, 2020, 38: 9504. doi: 10.1200/JCO.2020.38.15_suppl.9504 |